Cell Cycle Control Related Proteins (p53, p21, and Rb) and Transforming Growth Factor β (TGFβ) in Benign and Carcinomatous (In Situ and Infiltrating) Human Breast: Implications in Malignant Transformations

REFERENCES

• Simpson J. F., Page D. L. The p53 tumor suppressor gene in ductal carcinoma in situ of the breast. Am. J. Pathol. 2000; 156: 5–6, [CSA]
   PubMed Web of Science ®Google Scholar
• Finlay C. A., Hinds P. W., Levine A. J. The p53 protooncogene can act as a suppressor of transformation. Cell 1989; 57: 1083–1090, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nigro J. M., Baker S. J., Preisingerr A. C., Jessup J. M., Hostetter R., et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705–708, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Seshandri R., Leong A. S., McCauld K., Firgaira F. A., Setlur V., Horsfall D. J., et al. Relationship between p53 gene abnormalities and other tumour characteristics in breast cancer prognosis. Int. J. Cancer 1996; 69: 135–141, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Isola J., Visakorpi T., Holli K., Kallioniemi O P. Association of overexpression of tumor suppresor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl. Cancer Ins. 1992; 84: 1109–1114, [CSA]
   PubMed Web of Science ®Google Scholar
• Iwaya K., Tsuda H., Hiraide K., Tamaki H., Tamakuma S., et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn. J. Cancer Res. 1991; 82: 835–840, [CSA]
   PubMedGoogle Scholar
• Waldman T., Kinzler K. W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995; 55: 5187–5190, [CSA]
   PubMed Web of Science ®Google Scholar
• El-Deiry W. S., Tokino T., Waldman T., Oliner J. D., Velculescu V. E., Burell M., et al. Topological control of p21 (Waf1/cip1) expression in normal and neoplastic tissues. Cancer Res. 1995; 55: 2910–2919, [CSA]
   PubMed Web of Science ®Google Scholar
• Diab S., Yu Y., Hilsenbeck S., Allred D., Elledge R. WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res. Treat. 1997; 43: 4099–4103, [CSA], [CROSSREF]
   Google Scholar
• Johnson E., Davison A., Hostetter R., Cook L., Thomas E., Quinlan D., et al. The expression of Waf-1 in node-negative infiltrating ductal breast carcinoma. Proc. Am. Assoc. Cancer Res. 1996; 37: 3905–3910, [CSA]
   Google Scholar
• Robson C. N., Gnanapragasam V., Byrne R. L., Collins A. T., Neal D. E. Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J. Endocrinol. 1999; 160: 257–266, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Caffo O., Doglioni C., Veronese S., Bonzanini M., Marchetti A., et al. Prognostic value of p21 (WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res. 1996; 2: 1591–1599, [CSA]
   PubMed Web of Science ®Google Scholar
• Sherr C. J. G1 phase progression: cycling on cue. Cell 1994; 79: 551–555, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dowdy S. F., Hinds P. W., Louie K., Reed S. I., Arnold A., et al. Physical interaction of the retinoblastoma protein with human d-cyclins. Cell 1993; 73: 499–511, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chen P. L., Scully P., Shew J., Wang J. Y., Lee W. H. Phosphorilation of the retinoblastoma gene product is modulated during the cell cycle and the cell differentiation. Cell 1989; 58: 1193–1198, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Blagosklonny M. V., Prabhu N. S., El-Deiry W. S. Defects in p21WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res 1997; 57: 320–325, [CSA]
   PubMedGoogle Scholar
• Dublin E. A., Patel N. K., Gillett C. E., Smith P., Peters G., Barnes D. M. Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int. J. Cancer 1998; 79: 71–75, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Botos J., Smith R., Kochevar D. T. Retinoblastoma function is a better indicator of cellular phenotype in cultured breast adenocarcinoma cells than retinoblastoma expression. Exp. Biol. Med. 2002; 227: 354–362, [CSA]
   PubMed Web of Science ®Google Scholar
• UICC, (International Union Against Cancer). TNM Classification of malignant tumor. International Union against Cancer, GenevaSwitzerland 1968
   Google Scholar
• Heffelfinger S., Yassin R., Miller M., Lower E. Cyclin D1, retinoblastoma, p53, and her2/neu protein expression in preinvasive breast pathologies: correlation with vascularity. Pathobiol. 2000; 68: 129–136, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schmitt F. C., Leal C., Lopes C. p53 protein expression and nuclear DNA content in breast intraductal proliferations. J. Pathol. 1995; 176: 233–241, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mommers E. C., Leonhart A. M., Falix F., Michalides R., Meijer C. J., et al. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of the same differentiation grade. J. Pathol. 2001; 194: 327–333, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gomm J. J., Smith J., Ryall G. K., Baillie R., Turnbull L., Coombes R. C. Localization of basic fibroblast growth factor and transforming growth factor beta 1 in the human mammary gland. Cancer Res. 1991; 51: 4685–4692, [CSA]
   PubMed Web of Science ®Google Scholar
• Rohan T. E., Hartwick W., Miller A. B., Kandel R. A. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J. Natl. Cancer Inst. 1998; 90: 1262–1269, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Winters Z. E., Hunt N. C., Bradburn M. J., Rovds J. A., Turkey H., et al. Subcellular localisation of cyclin B, Cdc2 and p21 (WAF1/CIP1) in breast cancer association with prognosis. Eur. J. Cancer 2001; 37: 2405–92412, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ioakim-Liossi A., Markopoulos C., Karakitsos P., Safioleas M., Gogas J., Vaiopoulos G. p53 protein expression in benign and malignant breast lesions. Acta Cytol. 1998; 42: 918–922, [CSA]
   PubMed Web of Science ®Google Scholar
• Lukas J., Niu N., Press M. F. p53 mutations and expression in breast carcinoma in situ. Am. J. Pathol. 2000; 156: 183–191, [CSA]
   PubMed Web of Science ®Google Scholar
• Tan P., Mo G., Ji C., NG E., Gao F., Bay B. Immunohistochemical expression of p53 protein in invasive breast carcinoma: clinopathologic correlations. Oncol. Reports 1999; 6: 1159–1163, [CSA]
   PubMed Web of Science ®Google Scholar
• Parl F., Schmidt B., Dupon W., Wagner R. Prognostic significance of Estrogen Receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grade. Cancer 1984; 54: 2237–2242, [CSA]
   PubMed Web of Science ®Google Scholar
• Putti T. C., El-Rehim D. M., Rakha E. A., Paish C. E., Lee A. H., et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod. Pathol. 2005; 18: 26–35, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ioachim E. E., Malamou-Mitsi V., Kamina S. A., Goussia A. C., Agnantis N. J. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices. Anticancer Res. 2000; 20: 4221–4225, [CSA]
   PubMed Web of Science ®Google Scholar
• Stark G. R., Taylor W. R. Analyzing the G2/M checkpoint. Methods Mol Biol. 2004; 280: 51–82, [CSA]
   PubMedGoogle Scholar
• Lotem J., Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in deifferentiation-competent and defective myeloid leukemic cells. Growth Differ. 1993; 3: 41–47, [CSA]
   Google Scholar
• Royuela M., Arenas M. I., Bethencourt F. R., Sanchez-Chapado M., Fraile B., et al. Immunoexpression of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates. Eur. Cytokine Netw. 2001; 12: 654–663, [CSA]
   PubMed Web of Science ®Google Scholar
• Barbareschi M., Caffo O., Doglioni A., Fina P., Mazchetti A., et al. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1, expression, p53 gene and protein alterations and relapse-free survival. Br. J. Cancer 1996; 74: 208–215, [CSA]
   PubMed Web of Science ®Google Scholar